Rotherham, Doncaster and South Humber NHS Foundation Trust (RDaSH) patient group direction (PGD) for the supply and administration of subcutaneous medroxyprogesterone acetate (SC-DMPA) injection in RDaSH.
This patient group direction (PGD) must only be used by registered professionals who have been named and authorised by their organisation to practise under it (see appendix A). The most recent and in date final signed version of the PGD must be used.
To download this PGD please follow the link: Sexual health subcutaneous medroxyprogesterone acetate (staff access only) (opens in new window).
To access the equality impact assessment for this policy, please see the overarching equality impact assessment.
Page last reviewed: January 17, 2025
Next review due: January 17, 2026
Problem with this page?
Please tell us about any problems you have found with this web page.
Report a problem